Completed PHASE3 INTERVENTIONAL 3-arm NCT04158076

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

A Randomized, Double-blind, Active-controlled, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2071 and AD-2073 in Patients With Primary Hypercholesterolemia and Essential Hypertension

Sponsor: Addpharma Inc.

Conditions Hypercholesterolemia Hypertension

Interventions Ezetimibe/Rosuvastatin Telmisartan Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET

Updated 6 times since 2019 Last updated: May 10, 2021 Started: Jan 23, 2020 Primary completion: Jan 14, 2021 Completion: Jan 14, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypercholesterolemia and Hypertension, this trial is completed. The trial is conducted by Addpharma Inc. and has accumulated 6 data snapshots since 2020. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2021 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE3

Status: Not Yet Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addpharma Inc.

Data source: Addpharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea